AkaRx Inc. licenses tetrac patents from Beartownpharma Inc.

February 01, 2007

PARAMUS, NJ., February 1-- AkaRx, Inc., a Paramus, New Jersey biopharmaceutical company announced today that they have licensed from BeartownPharma, Inc., of Underhill, Vermont the patents for a new drug being developed for the treatment of patients with thyroid cancer. The drug, AKR-201, (tetraiodothyroacetic acid / "tetrac") is a metabolite of thyroid hormone.

The agreement calls for upfront and milestone payments to be made to BeartownPharma as well as royalty on net sales of the product.

AkaRx will develop AKR-201 for the management of patients with follicular or papillary carcinoma of the thyroid.

Patients with carcinoma of the thyroid gland are currently treated by surgically removing their thyroid gland and subsequently administering radioactive iodine to eliminate remaining thyroid cancer cells. They are then given daily thyroid hormone to replace their natural thyroid hormone.

Often, the amount of thyroid hormone given is higher than what is needed to replace their natural thyroid hormone. These suppressive doses are given to shut down the production in the pituitary gland of a hormone called TSH (Thyroid Stimulating Hormone). TSH stimulates the thyroid gland to produce thyroid hormone and can also stimulate the growth of residual thyroid cancer cells. Suppression of TSH can reduce this effect. However, patients treated with suppressive doses of thyroid hormone are, in effect, hyperthyroid and have the associated risks of heart rhythm abnormalities (atrial fibrillation) and loss of bone density (osteoporosis).

AKR-201 is expected, in combination with replacement doses of thyroid hormone, to suppress production of TSH without causing the side effects of hyperthyroidism.

There are approximately 350,000 patients who have been diagnosed with thyroid cancer in the United States with an estimated 30,000 newly diagnosed cases per year.

AkaRx plans to file an IND with the Food and Drug Administration to begin clinical trials with AKR-201 by the middle of 2007.
Additional information can be obtained at www.akarx.com or by contacting John Gregg at (201) 909-3049 / gregg@akarx.com.

AkaRx, Inc.

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.